Shares of Pacific Biosciences of California (NASDAQ:PACB) ended Thursday session in red amid volatile trading. The shares closed down -0.03 points or -0.36% at $8.30 with 1.16 million shares getting traded. Post opening the session at $8.35, the shares hit an intraday low of $8.20 and an intraday high of $8.44 and the price vacillated in this range throughout the day. The company has a market cap of $753.52 million and the numbers of outstanding shares have been calculated to be 91.88 million shares.
Pacific Biosciences of California (PACB) on Aug. 04, 2016 announced it has released a set of key updates for the Sequel™ System, the company’s latest product based on its Single Molecule, Real-Time (SMRT®) Sequencing technology. The new release provides performance improvements via updated sequencing chemistry, optimized sample clean-up protocols, and associated software that together further improve read lengths, throughput and accuracy of the system. In addition, as customers upgrade their Sequel Systems to the new software and chemistry, they will no longer be subject to the supply constraints for SMRT Cells that were in effect earlier this year.
“These updates reinforce our continued commitment to improving SMRT Sequencing throughput, read length, and accuracy through optimized protocols and chemistry to enhance applications, such as de novo assembly, targeted sequencing, and the Iso-Seq™ method for RNA analysis,” said Kevin Corcoran, Senior Vice President of Market Development for Pacific Biosciences. “With this release, we have removed SMRT Cell supply constraints as we begin to source SMRT Cells for the Sequel System from our high-volume supplier.”
Yi Han, Ph.D., Assistant Professor in the Department of Molecular and Human Genetics at Baylor College of Medicine, who had early access to the new chemistry and software commented: “We are very impressed with the data we are getting with the latest update to the Sequel chemistry, sample prep, and software. As one of the first adopters of SMRT Sequencing, we appreciate how PacBio has partnered with us since 2010 to continually make improvements to the technology that directly benefit our research.”
Shares of Envision Healthcare Holdings Inc (NYSE:EVHC) ended Thursday session in red amid volatile trading. The shares closed down -0.01 points or -0.05% at $21.45 with 4.78 million shares getting traded. Post opening the session at $21.50, the shares hit an intraday low of $21.17 and an intraday high of $21.50 and the price vacillated in this range throughout the day. The company has a market cap of $4.04 billion and the numbers of outstanding shares have been calculated to be 187.17 million shares.
Envision Healthcare Holdings Inc (EVHC) on August 4, 2016 reported results from operations for the three months and six months ended June 30, 2016.
- Net revenue of $1.64 billion, an increase of 21.2%;
- Net income of $28.4 million compares with $52.4 million;
- Adjusted EBITDA of $172.0 million compares with $162.8 million;
- GAAP diluted earnings per share (EPS) was $0.15 and compares with $0.27; and
- Adjusted diluted EPS was $0.34 and compares with $0.37.
“Our results for the second quarter of 2016 reflect solid operating performance for our EmCare hospital-based physician services and legacy AMR operations,” said William A. Sanger, chairman, president and chief executive officer. “Our AMR financial results were impacted by investments made in certain Rural/Metro markets to meet customer service expectations and establish our position as valued partners in these communities. In addition, we experienced a delay in the expected earnings contribution from Evolution Health’s recently launched Florida health plan contract. We remain confident that we will achieve our targeted financial performance for both Rural/Metro and Evolution’s health plan contract during the first half of 2017. Our 2016 outlook is being updated to reflect the timing of expected improvements.”